{"id":"https://openalex.org/W1535011663","doi":"https://doi.org/10.1111/ddg.12100","title":"Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha\u20102b in metastatic melanoma (phase II DeCOG trial)","display_name":"Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha\u20102b in metastatic melanoma (phase II DeCOG trial)","publication_year":2013,"publication_date":"2013-07-23","ids":{"openalex":"https://openalex.org/W1535011663","doi":"https://doi.org/10.1111/ddg.12100","mag":"1535011663","pmid":"https://pubmed.ncbi.nlm.nih.gov/23879405"},"language":"en","primary_location":{"id":"doi:10.1111/ddg.12100","doi":"https://doi.org/10.1111/ddg.12100","is_oa":false,"landing_page_url":"https://doi.org/10.1111/ddg.12100","pdf_url":null,"source":{"id":"https://openalex.org/S4210169996","display_name":"JDDG Journal der Deutschen Dermatologischen Gesellschaft","issn_l":"1610-0379","issn":["1610-0379","1610-0387"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064998138","display_name":"Annette Degen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I34809795","display_name":"Medizinische Hochschule Hannover","ror":"https://ror.org/00f2yqf98","country_code":"DE","type":"education","lineage":["https://openalex.org/I34809795"]}],"countries":["DE"],"is_corresponding":true,"raw_author_name":"Annette Degen","raw_affiliation_strings":["Department of Dermatology and Allergology, Hannover Medical School, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology and Allergology, Hannover Medical School, Germany","institution_ids":["https://openalex.org/I34809795"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022293880","display_name":"Michael Weichenthal","orcid":"https://orcid.org/0000-0002-9060-4961","observed_orcids":["https://orcid.org/0000-0002-9060-4961"]},"institutions":[{"id":"https://openalex.org/I4210112713","display_name":"University Hospital Schleswig-Holstein","ror":"https://ror.org/01tvm6f46","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210112713"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Michael Weichenthal","raw_affiliation_strings":["Clinic for Dermatology, Venereology and Allergology, University Clinic Schleswig-Holstein, Campus Kiel, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinic for Dermatology, Venereology and Allergology, University Clinic Schleswig-Holstein, Campus Kiel, Germany","institution_ids":["https://openalex.org/I4210112713"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057381405","display_name":"Selma Ugurel","orcid":"https://orcid.org/0000-0002-9384-6704","observed_orcids":["https://orcid.org/0000-0002-9384-6704"]},"institutions":[{"id":"https://openalex.org/I15766117","display_name":"University of Graz","ror":"https://ror.org/01faaaf77","country_code":"AT","type":"education","lineage":["https://openalex.org/I15766117"]},{"id":"https://openalex.org/I4210126310","display_name":"Universit\u00e4tsklinikum W\u00fcrzburg","ror":"https://ror.org/03pvr2g57","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210126310"]}],"countries":["AT","DE"],"is_corresponding":false,"raw_author_name":"Selma Ugurel","raw_affiliation_strings":["Clinic and Polyclinic for Dermatology, Venereology and Allergology  University Clinic W\u00fcrzburg Germany","University Clinic for Dermatology and Venereology, Graz, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinic and Polyclinic for Dermatology, Venereology and Allergology  University Clinic W\u00fcrzburg Germany","institution_ids":["https://openalex.org/I4210126310"]},{"raw_affiliation_string":"University Clinic for Dermatology and Venereology, Graz, Austria","institution_ids":["https://openalex.org/I15766117"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015624855","display_name":"Uwe Trefzer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I7877124","display_name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","ror":"https://ror.org/001w7jn25","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I7877124"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Uwe Trefzer","raw_affiliation_strings":["Clinic for Dermatology, Venereology and Allergology, Charit\u00e9 \u2013  University Medicine Berlin Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinic for Dermatology, Venereology and Allergology, Charit\u00e9 \u2013  University Medicine Berlin Germany","institution_ids":["https://openalex.org/I7877124"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054330151","display_name":"Katharina Kilian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3018771216","display_name":"LMU Klinikum","ror":"https://ror.org/02jet3w32","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I3018771216","https://openalex.org/I8204097"]},{"id":"https://openalex.org/I8204097","display_name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","ror":"https://ror.org/05591te55","country_code":"DE","type":"education","lineage":["https://openalex.org/I8204097"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Katharina Kilian","raw_affiliation_strings":["Clinic and Polyclinic for Dermatology and Allergology, University Clinic Munich (LMU), Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinic and Polyclinic for Dermatology and Allergology, University Clinic Munich (LMU), Germany","institution_ids":["https://openalex.org/I3018771216","https://openalex.org/I8204097"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001548963","display_name":"Claus Garbe","orcid":"https://orcid.org/0000-0001-8530-780X","observed_orcids":["https://orcid.org/0000-0001-8530-780X"]},"institutions":[{"id":"https://openalex.org/I4210094118","display_name":"Universit\u00e4tsklinikum T\u00fcbingen","ror":"https://ror.org/00pjgxh97","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210094118"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Claus Garbe","raw_affiliation_strings":["University Clinic for Dermatology  T\u00fcbingen Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Clinic for Dermatology  T\u00fcbingen Germany","institution_ids":["https://openalex.org/I4210094118"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083190162","display_name":"Friederike Egberts","orcid":"https://orcid.org/0000-0003-0839-4350","observed_orcids":["https://orcid.org/0000-0003-0839-4350"]},"institutions":[{"id":"https://openalex.org/I4210112713","display_name":"University Hospital Schleswig-Holstein","ror":"https://ror.org/01tvm6f46","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210112713"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Friederike Egberts","raw_affiliation_strings":["Clinic for Dermatology, Venereology and Allergology, University Clinic Schleswig-Holstein, Campus Kiel, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinic for Dermatology, Venereology and Allergology, University Clinic Schleswig-Holstein, Campus Kiel, Germany","institution_ids":["https://openalex.org/I4210112713"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021867367","display_name":"L\u00ecdia Marilia Poppe","orcid":"https://orcid.org/0000-0003-3896-705X","observed_orcids":["https://orcid.org/0000-0003-3896-705X"]},"institutions":[{"id":"https://openalex.org/I4210126310","display_name":"Universit\u00e4tsklinikum W\u00fcrzburg","ror":"https://ror.org/03pvr2g57","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210126310"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"L\u00ecdia Marilia Poppe","raw_affiliation_strings":["Clinic and Polyclinic for Dermatology, Venereology and Allergology  University Clinic W\u00fcrzburg Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinic and Polyclinic for Dermatology, Venereology and Allergology  University Clinic W\u00fcrzburg Germany","institution_ids":["https://openalex.org/I4210126310"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044736874","display_name":"Axel Hauschild","orcid":"https://orcid.org/0000-0002-1212-9587","observed_orcids":["https://orcid.org/0000-0002-1212-9587"]},"institutions":[{"id":"https://openalex.org/I4210112713","display_name":"University Hospital Schleswig-Holstein","ror":"https://ror.org/01tvm6f46","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210112713"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Axel Hauschild","raw_affiliation_strings":["Clinic for Dermatology, Venereology and Allergology, University Clinic Schleswig-Holstein, Campus Kiel, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinic for Dermatology, Venereology and Allergology, University Clinic Schleswig-Holstein, Campus Kiel, Germany","institution_ids":["https://openalex.org/I4210112713"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015081105","display_name":"Ralf Gutzmer","orcid":"https://orcid.org/0000-0001-7921-2820","observed_orcids":["https://orcid.org/0000-0001-7921-2820"]},"institutions":[{"id":"https://openalex.org/I34809795","display_name":"Medizinische Hochschule Hannover","ror":"https://ror.org/00f2yqf98","country_code":"DE","type":"education","lineage":["https://openalex.org/I34809795"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Ralf Gutzmer","raw_affiliation_strings":["Department of Dermatology and Allergology, Hannover Medical School, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology and Allergology, Hannover Medical School, Germany","institution_ids":["https://openalex.org/I34809795"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5064998138"],"corresponding_institution_ids":["https://openalex.org/I34809795"],"apc_list":{"value":4480,"currency":"USD","value_usd":4480},"apc_paid":null,"fwci":2.1124,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":{"value":0.85173452,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"11","issue":"9","first_page":"846","last_page":"853"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.9692000150680542,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12937","display_name":"Chemotherapy-related skin toxicity","score":0.9692000150680542,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.020600000396370888,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.002300000051036477,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.9150000214576721},{"id":"https://openalex.org/keywords/pegylated-interferon-alpha-2b","display_name":"pegylated interferon alpha-2b","score":0.9919999837875366},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.9639999866485596},{"id":"https://openalex.org/keywords/cutaneous-adverse-effects","display_name":"cutaneous adverse events","score":0.8600000143051147},{"id":"https://openalex.org/keywords/skin-rash","display_name":"rash","score":0.7689999938011169},{"id":"https://openalex.org/keywords/hand-foot-syndrome","display_name":"hand-foot syndrome","score":0.9959999918937683},{"id":"https://openalex.org/keywords/alopecia","display_name":"hair loss","score":0.9959999918937683},{"id":"https://openalex.org/keywords/pruritus","display_name":"pruritus","score":0.996999979019165},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.621999979019165},{"id":"https://openalex.org/keywords/dose-reduction","display_name":"dose reduction","score":0.718999981880188},{"id":"https://openalex.org/keywords/dermatological-treatment","display_name":"dermatological treatment","score":0.5649999976158142}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9550029039382935},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.7861467003822327},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.7114604711532593},{"id":"https://openalex.org/C3454156","wikidata":"https://www.wikidata.org/wiki/Q1144241","display_name":"Side effect (computer science)","level":2,"score":0.6756047010421753},{"id":"https://openalex.org/C2776461080","wikidata":"https://www.wikidata.org/wiki/Q7160835","display_name":"Pegylated interferon","level":5,"score":0.5882429480552673},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.536844789981842},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.529290497303009},{"id":"https://openalex.org/C2909179924","wikidata":"https://www.wikidata.org/wiki/Q6046488","display_name":"Alpha interferon","level":3,"score":0.5236812829971313},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4656202495098114},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.4213916063308716},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.37314653396606445},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.34908705949783325},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.33856603503227234},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.30304089188575745},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.14668893814086914},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.12590858340263367},{"id":"https://openalex.org/C2780040827","wikidata":"https://www.wikidata.org/wiki/Q421862","display_name":"Ribavirin","level":4,"score":0.06369704008102417},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.0},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C2776408679","wikidata":"https://www.wikidata.org/wiki/Q708693","display_name":"Hepatitis C virus","level":3,"score":0.0},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077157","descriptor_name":"Sorafenib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003875","descriptor_name":"Drug Eruptions","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D003875","descriptor_name":"Drug Eruptions","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005858","descriptor_name":"Germany","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009536","descriptor_name":"Niacinamide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009536","descriptor_name":"Niacinamide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D010671","descriptor_name":"Phenylurea Compounds","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D015897","descriptor_name":"Comorbidity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015984","descriptor_name":"Causality","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015995","descriptor_name":"Prevalence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/ddg.12100","doi":"https://doi.org/10.1111/ddg.12100","is_oa":false,"landing_page_url":"https://doi.org/10.1111/ddg.12100","pdf_url":null,"source":{"id":"https://openalex.org/S4210169996","display_name":"JDDG Journal der Deutschen Dermatologischen Gesellschaft","issn_l":"1610-0379","issn":["1610-0379","1610-0387"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft","raw_type":"journal-article"},{"id":"pmid:23879405","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23879405","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":32,"referenced_works":["https://openalex.org/W1693873467","https://openalex.org/W1968151389","https://openalex.org/W1970263079","https://openalex.org/W1996159866","https://openalex.org/W1996283150","https://openalex.org/W1996669689","https://openalex.org/W1999966467","https://openalex.org/W2004162397","https://openalex.org/W2012072673","https://openalex.org/W2013683617","https://openalex.org/W2017073868","https://openalex.org/W2031188948","https://openalex.org/W2038965395","https://openalex.org/W2041851693","https://openalex.org/W2052368352","https://openalex.org/W2074354102","https://openalex.org/W2087332538","https://openalex.org/W2089131417","https://openalex.org/W2092917054","https://openalex.org/W2099289479","https://openalex.org/W2116177733","https://openalex.org/W2130913838","https://openalex.org/W2134210187","https://openalex.org/W2135678285","https://openalex.org/W2156497634","https://openalex.org/W2157207652","https://openalex.org/W2162407658","https://openalex.org/W2168742889","https://openalex.org/W2169979891","https://openalex.org/W2314874837","https://openalex.org/W2465751741","https://openalex.org/W4256189622"],"related_works":["https://openalex.org/W2130913838","https://openalex.org/W2530611189","https://openalex.org/W1964038956","https://openalex.org/W2590455676","https://openalex.org/W1861373669","https://openalex.org/W2602810717","https://openalex.org/W1996669689","https://openalex.org/W2012072673","https://openalex.org/W2123334992","https://openalex.org/W2126633948"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1,57],"OBJECTIVES:":[2],"During":[3],"a":[4,60,75,218],"clinical":[5,181],"study":[6,34,63],"with":[7,46,71,153,180],"combined":[8],"therapy":[9,140,148],"of":[10,18,48,77,139,147,173,188,208,215],"sorafenib":[11,78],"and":[12,26,51,84,121,144,149],"pegylated":[13,85],"interferon":[14,49,86,190],"alpha-2b":[15,87,191],"(SoraPeg":[16],"study)":[17],"the":[19,127,209],"German":[20],"Dermatologic":[21],"Oncology":[22],"Group":[23],"(ADO/DeCOG),":[24],"multiple":[25],"severe":[27],"cutaneous":[28,39,96,107,128,174,194,210],"side":[29,40,97,108,129,175,195,211],"effects":[30,98,176,196,212],"were":[31,99,133,158],"observed.":[32],"This":[33],"sought":[35],"to":[36,126],"analyze":[37],"these":[38],"effects,":[41,109,130],"particularly":[42,110],"because":[43],"future":[44],"studies":[45],"combinations":[47],"alpha":[50],"targeted":[52],"therapies":[53],"are":[54],"planned.":[55],"PATIENTS":[56],"METHODS:":[58],"In":[59],"multicenter":[61],"phase-II-DeCOG":[62],"(NCT00623402)":[64],"in":[65,135,141,150,162,167],"10":[66,136,142],"dermato-oncology":[67],"centers,":[68],"55":[69],"patients":[70,103,216],"metastatic":[72],"melanoma":[73],"received":[74],"combination":[76,187],"(2":[79],"x":[80],"400":[81],"mg/day":[82],"orally)":[83],"(3":[88],"\u03bcg/kg":[89],"body":[90],"weight":[91],"1":[92],"x/week":[93],"subcutaneously).":[94],"All":[95],"documented.":[100],"RESULTS:":[101],"Forty-one":[102],"(74.5":[104],"%)":[105,120,165],"developed":[106],"exanthems":[111],"(51.2":[112],"%),":[113,117],"hand-foot":[114],"syndrome":[115],"(36.5":[116,119],"alopecia":[118],"pruritus":[122],"(24.4":[123],"%).":[124,170],"Due":[125],"dose":[131,219],"reductions":[132],"required":[134,217],"patients,":[137],"interruption":[138],"cases":[143],"permanent":[145],"discontinuation":[146],"one":[151],"patient":[152],"extensive":[154],"follicular-cystic":[155],"lesions.":[156],"Exanthems":[157],"seen":[159],"more":[160,193],"frequently":[161],"women":[163],"(76.2":[164],"than":[166,197],"men":[168],"(23.8":[169],"The":[171,186],"occurrence":[172],"was":[177],"not":[178],"correlated":[179],"outcome":[182],"or":[183],"prognosis.":[184],"CONCLUSIONS:":[185],"sorafenib/pegylated":[189],"caused":[192],"have":[198],"been":[199],"reported":[200],"for":[201],"single":[202],"agents.":[203],"Despite":[204],"intensive":[205],"dermatologic":[206],"management":[207],"24":[213],"%":[214],"modification.":[220]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":5}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}